Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Quetiapine for Pediatric Delirium

Trial Profile

Efficacy of Quetiapine for Pediatric Delirium

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Delirium
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 31 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Dec 2015 Planned end date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top